NextFin news, On August 25, 2025, in Washington, D.C., Robert F. Kennedy Jr., Secretary of Health and Human Services (HHS), has intensified efforts to reform the U.S. vaccine system, prompting warnings from vaccine manufacturers that his policies could force vaccines off the market.
Kennedy's strategy focuses on the Vaccine Injury Compensation Program (VICP), a federal fund that compensates individuals injured by vaccines. Established in 1988, the VICP has paid out over $5 billion and shields manufacturers from most liability claims. Kennedy aims to revise the program, including potentially adding autism and allergies as compensable injuries, despite scientific consensus rejecting a vaccine-autism link.
Legal experts and public health leaders caution that expanding the VICP to cover such claims could bankrupt the fund, exposing pharmaceutical companies to increased liability risks. This financial pressure might compel manufacturers to cease vaccine production, as vaccines generally yield low profits and companies seek to avoid costly lawsuits.
Sources familiar with internal HHS discussions report that Kennedy has placed vaccine skeptics in key regulatory roles at the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA). He has also restructured federal vaccine advisory committees, removing traditional medical organizations and appointing members skeptical of vaccine safety.
In addition, Kennedy's department recently halted $500 million in grants and contracts for mRNA vaccine research, including improved COVID-19 vaccines, a move that experts warn could hinder U.S. preparedness for future pandemics.
Kennedy publicly states he is "pro-safety, pro-transparency, and pro-accountability," but his critics argue his actions undermine vaccine availability and public health. HHS spokesperson Vianca Rodriguez Feliciano emphasized that Kennedy is not anti-vaccine.
These developments have sparked concern among vaccine manufacturers and legal scholars that Kennedy's policies, if fully implemented, could reduce vaccine access in the U.S. and increase public health risks.
Sources: The Morning Call (mcall.com), Mercury News (mercurynews.com), KFF Health News (kffhealthnews.org), BioPharma Dive (biopharmadive.com), Reuters (reuters.com).
Explore more exclusive insights at nextfin.ai.
